Relapse outcomes were largely null in major RCTs, including SOLAR and VIDAMS, despite numerically lower ARR in some analyses ...
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on ...
Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few ...
Chronic kidney disease (CKD) risk stratification that flagged high-risk patients in the electronic medical record, paired ...
Long-acting injectable HIV pre-exposure prophylaxis (LAI PrEP) could significantly reduce HIV infections, but disparate ...
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers. Across many disease ...
Infectious diseases (ID) and HIV clinicians can shape federal and state policy by pairing patient stories with sustained, ...
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data ...
Of 1125 adults with sarcoma treated at a single US center, 502 (44.6%) reported mild, moderate, or severe financial toxicity ...
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
Moderator Ricardo Costa, MD, MSc, led colleagues from Moffitt Cancer Center in the first panel, “Targeted Success: ...
Hiddo J. Heerspink, PhD, is a professor of clinical trials and personalized medicine at University Medical Center Groningen in the Netherlands.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results